Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Prakash Mistry

Showing results (1-10 of 15) with videos related to

Pageof 2
Sort By:
Current Opinion in Investigational Drugs (London, England : 2000)|December 13, 2002
ONT-093 (Ontogen)Prakash Mistry, Adrian Folkes
The Journal of Biological Chemistry|August 20, 2004
Novel DNA bis-intercalation by MLN944, a potent clinical bisphenazine anticancer drugJixun Dai, Chandanamalie Punchihewa, Prakash Mistry, et al.
Anti-Cancer Drugs|December 13, 2006
Mode of action of the novel phenazine anticancer agents XR11576 and XR5944Louisa J Lewis, Prakash Mistry, Peter A Charlton, et al.
Anti-Cancer Drugs|September 16, 2005
Preclinical anti-tumor activity of XR5944 in combination with carboplatin or doxorubicin in non-small-cell lung carcinomaSusan M Harris, John A Scott, Jeffrey L Brown, et al.
Cancer Chemotherapy and Pharmacology|August 6, 2008
Effect of phenazine compounds XR11576 and XR5944 on DNA topoisomerasesAndrew G Jobson, Elaine Willmore, Michael J Tilby, et al.
Cancer Research|February 20, 2004
Pheophorbide a is a specific probe for ABCG2 function and inhibitionRobert W Robey, Kenneth Steadman, Orsolya Polgar, et al.
Bioorganic & Medicinal Chemistry Letters|January 30, 2002
Structure-activity relationships for analogues of the phenazine-based dual topoisomerase I/II inhibitor XR11576Shouming Wang, Warren Miller, John Milton, et al.
Plos One|August 8, 2009
H4 histamine receptors mediate cell cycle arrest in growth factor-induced murine and human hematopoietic progenitor cellsAnne-France Petit-Bertron, François Machavoine, Marie Paule Defresne, et al.
Anti-Cancer Drugs|March 27, 2002
In vitro and in vivo characterization of XR11576, a novel, orally active, dual inhibitor of topoisomerase I and IIPrakash Mistry, Alistair J Stewart, Wendy Dangerfield, et al.
Journal of Medicinal Chemistry|January 25, 2002
Structure-activity relationships for pyrido-, imidazo-, pyrazolo-, pyrazino-, and pyrrolophenazinecarboxamides as topoisomerase-targeted anticancer agentsSwarna A Gamage, Julie A Spicer, Gordon W Rewcastle, et al.
Pageof 2

Showing results (1-10 of 15) with videos related to

Sort By:
Pageof 2
Current Opinion in Investigational Drugs (London, England : 2000)|December 13, 2002
ONT-093 (Ontogen)Prakash Mistry, Adrian Folkes
The Journal of Biological Chemistry|August 20, 2004
Novel DNA bis-intercalation by MLN944, a potent clinical bisphenazine anticancer drugJixun Dai, Chandanamalie Punchihewa, Prakash Mistry, et al.
Anti-Cancer Drugs|December 13, 2006
Mode of action of the novel phenazine anticancer agents XR11576 and XR5944Louisa J Lewis, Prakash Mistry, Peter A Charlton, et al.
Anti-Cancer Drugs|September 16, 2005
Preclinical anti-tumor activity of XR5944 in combination with carboplatin or doxorubicin in non-small-cell lung carcinomaSusan M Harris, John A Scott, Jeffrey L Brown, et al.
Cancer Chemotherapy and Pharmacology|August 6, 2008
Effect of phenazine compounds XR11576 and XR5944 on DNA topoisomerasesAndrew G Jobson, Elaine Willmore, Michael J Tilby, et al.
Cancer Research|February 20, 2004
Pheophorbide a is a specific probe for ABCG2 function and inhibitionRobert W Robey, Kenneth Steadman, Orsolya Polgar, et al.
Bioorganic & Medicinal Chemistry Letters|January 30, 2002
Structure-activity relationships for analogues of the phenazine-based dual topoisomerase I/II inhibitor XR11576Shouming Wang, Warren Miller, John Milton, et al.
Plos One|August 8, 2009
H4 histamine receptors mediate cell cycle arrest in growth factor-induced murine and human hematopoietic progenitor cellsAnne-France Petit-Bertron, François Machavoine, Marie Paule Defresne, et al.
Anti-Cancer Drugs|March 27, 2002
In vitro and in vivo characterization of XR11576, a novel, orally active, dual inhibitor of topoisomerase I and IIPrakash Mistry, Alistair J Stewart, Wendy Dangerfield, et al.
Journal of Medicinal Chemistry|January 25, 2002
Structure-activity relationships for pyrido-, imidazo-, pyrazolo-, pyrazino-, and pyrrolophenazinecarboxamides as topoisomerase-targeted anticancer agentsSwarna A Gamage, Julie A Spicer, Gordon W Rewcastle, et al.
Pageof 2